Eledon Pharmaceuticals, Inc. ELDN 深 滬
等待開盤 09-24 09:30:00 美东时间
2.72
-0.170
-5.88%
華盛通- 最 高2.94
- 今 開2.90
- 成交量 132.29万股
- 最 低 2.685
- 昨 收 2.89
- 總市值 2.21亿
- 52周最高 4.60
- 市盈率 靜 --
- 換手率 1.63%
- 52周最低 1.35
- 委 比 29.35%
- 總股本 8126.12万
- 歷史最高 154.98
- 量 比 1.37
- 振 幅 8.82%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six m...
09-22 19:11
Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six m...
09-22 19:10
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
Eledon Pharmaceuticals announced progress in its tegoprubart development programs for islet cell and kidney transplantation. Key updates include IND submission for a registrational study in type 1 diabetes patients undergoing islet cell transplantation, enrollment of first patients in an investigator-initiated study for islet transplant recipients with renal dysfunction, and compassionate use dosing of tegoprubart for conversion from tacrolimus i...
09-03 11:00
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from the same period last year.
08-14 04:30
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Zurich-based NewcelX Ltd. announced a private placement of 347,134 common shares at a 20% premium to its July 30 closing price, with warrants exercisable at 132% of that price. The offering, including participation from existing shareholders, is expected to close on Aug. 14. Proceeds will support the advancement of NCEL-101, the company's lead type 1 diabetes program, following a successful FDA Pre-IND meeting. CEO Ronen Twito highlighted investo...
07-31 13:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Rodman & Renshaw analyst Seema Sheoran initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-21 19:53
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significa...
07-01 21:33
Eledon Pharmaceuticals Expands Authorized Shares After Stockholder Vote
The latest update is out from Eledon Pharmaceuticals ( ($ELDN) ). At its Annual...
06-23 06:47
Eledon Pharma Announces New Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation, Presented At ATC 2026
Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73 m² advantage at month 18 versus tacrolimus (74 vs. 61 mL/min/1.73 m²; p<0.05) No biopsy-proven acute rejection (BPAR) events were observed in tegoprubart-treated pat...
06-22 19:15
